Despite recent improvements in immunotherapy, cancer still is a major threat to humans in western societies. To further improve the immunotherapy of cancer we have started a collaboration with the pharmaceutical company Apo-T. This therapy is based on the application of nanobodies: antibody fragments obtained from Llama’s. The project aims to generate nanobodies binding to tumor specific markers, which are presented on the surface of cancer cells as complexes of peptides bound to MHC-I proteins.
Within the project, nanobodies will be developed binding to peptide/MHC-complexes. Peptides are derived from MAGE-A, which is an intracellular biomarker for the early events of oncogenic transformation, tumor invasion and metastasis. As the Postdoc Researcher you will, together with a technician, fully characterize the obtained nanobodies using structural and cell biology methods. In addition, you will investigate the application of the novel nanobodies to specifically kill cancer cells. Different approaches will be evaluated: nanobody-drug conjugates, bispecific T-cell engagers (BITE) and/or CAR-T cells.
To excel in this role you enjoy being part of a driven multidisciplinary team. Furthermore, you are a motivated Postdoctoral Researcher with interest in the further applications of nanobodies in immunotherapy of cancer and you have: